Perrigo Sales Reach Record Highs Despite Manufacturing Restrictions
This article was originally published in The Tan Sheet
Acquisitions and new products helped Perrigo grow quarterly revenue 23% to $718 million, despite manufacturing restraints related to an FDA warning letter.
You may also be interested in...
Perrigo Takes Two Steps Forward: Generic Allegra Launch, Manufacturing Compliance
Perrigo stokes momentum behind already healthy sales growth with significant steps in separate areas: a green light for regulatory compliance at its main manufacturing plant, and the launch of its generic OTC versions of Sanofi-Aventis' Allegra.
Prestige CEO Mannelly Sees Change In Retail "Headwinds" Giving Brands More Shelf Space
In a year-and-a-half of heading Prestige Brands Holdings, Matthew Mannelly has been a change agent for the consumer health products firm.
Perrigo Gets "Wake-Up Call" In FDA Warning Letter
Perrigo prioritized correcting manufacturing problems that drew an FDA warning, advising the firm to prevent human errors with tighter quality control, according to CEO Joseph Papa